Journal Mobile Options
Table of Contents
Vol. 71, No. 5-6, 2006
Issue release date: October 2007
Oncology 2006;71:456–459
(DOI:10.1159/000107111)

Prognosis of Occult Breast Carcinoma Presenting as Isolated Axillary Nodal Metastasis

Varadarajan R. · Edge S.B. · Yu J. · Watroba N. · Janarthanan B.R.
aDepartments of Medicine and Surgical Oncology, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, N.Y., and bDepartment of Medicine, Rochester General Hospital, Rochester, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Axillary metastasis from an occult breast carcinoma is an uncommon presentation and presents a therapeutic dilemma. The objective of this study is to describe the presenting clinical features, management approach and treatment outcomes for occult breast carcinoma. We conducted a retrospective review of patients who presented with axillary nodal metastases from an occult breast carcinoma between 1997 and 2004 at the Roswell Park Cancer Institute; 2,150 patients were diagnosed and treated for breast cancer during this period. After excluding stage I and IV patients, we identified 642 who had disease metastatic to lymph nodes, 10 of these had no primary tumor in the breast despite a thorough evaluation including bilateral mammography and breast ultrasound. Of these, 7 had undergone breast magnetic resonance imaging as well. All patients underwent axillary nodal dissection. The breast was managed with radiotherapy alone in 8 patients, wide local excision with radiation therapy in 1 patient and 1 patient underwent mastectomy. No patient had a recurrence with a median 57 months of follow-up. Breast conservation with radiation therapy alone can be considered as a management option for women with occult breast cancer presenting with axillary nodal metastasis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Owen HW, Dockerty MB, Gray HK: Occult carcinoma of the breast. Surg Gynecol Obstet 1954;98:302–308.
  2. Patel J, Nemoto T, Rosner D, Dao TL, Pickren JW: Axillary lymph node metastasis from an occult breast cancer. Cancer 1981;47:2923–2927.
  3. Rosen PP: Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancer 1980;46:1298–1306.
  4. Tench DW, Page DL: The Breast: Comprehensive Management of Benign and Malignant Diseases, vol 2, ed. 2. Philadelphia, WB Saunders, 1998, pp 1447–1452.
  5. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P: Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272–1280.
  6. Hainsworth JD, Greco FA: Management of patients with cancer of unknown primary site. Oncology (Williston Park) 2000;14:563–574.
  7. Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA: Occult breast cancer presenting with axillary metastases: updated management. Arch Surg 1990;125:210–214.
  8. Fortunato L, Sorrento JJ, Golub RA, Cantu R: Occult breast cancer: a case report and review of the literature. NY State J Med 1992;92:555–557.
  9. Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M: Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990;66:1461–1467.
  10. Hainsworth JD, Greco FA: Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993;329:257–263.
  11. Morrow M, Schmidt RA, Bucci C: Breast conservation for mammographically occult carcinoma. Ann Surg 1998;227:502–506.
  12. Halsted W: The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1–19.
  13. Stomper PC, Waddell BE, Edge SB, Klippenstein DL: Breast MRI in the evaluation of patients with occult primary breast carcinoma. Breast J 1999;5:230–234.
  14. Knapper WH: Management of occult breast cancer presenting as an axillary metastasis. Semin Surg Oncol 1991;7:311–313.
  15. Vlastos G, Jean ME, Mirza AN, et al: Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 2001;8:425–431.
  16. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984;2:1102–1109.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00